Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
This is the last part of my discussion with Dr. Matthew Horton, a pathologist with a special training and a great expertise in lung pathology who works here in Seattle at a company called CellNetix.
We focus in this last one on the increasing focus on molecular markers in making clinical decisions and how this is changing the relationship of pathologists with oncologists, as well as the need for pathologists to provide this information in a timely way.
dr-horton-pt-3-transition-to-molecular-pathology-audio-podcast
dr-horton-pt-3-transition-to-molecular-pathology-transcript
dr-horton-pt-3-transition-to-molecular-pathology-figures
Next, we'll turn to coverage of imaging issues in cancer management.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…